Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Hui K. Gan"'
Autor:
Péron J; Julien Péron, Denis Maillet, and Benoit You, Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, Pierre-Bénite; Julien Péron, Hospices Civils de Lyon; Julien Péron and Benoit You, Université de Lyon, Lyon; Julien Péron, Centre National de la Recherche Scientifique Unité Mixte de Recherche 5558, Laboratoire de Biométrie et Biologie Evolutive, Equipe Biostatistique-Santé, Villeurbanne; Benoit You, EMR UCBL/HCL 3738, Faculté de Médecine Lyon-Sud, Oullins, France; Hui K. Gan, Joint Austin-Ludwig Oncology Unit, Austin Hospital, Melbourne, Victoria, Australia; Eric X. Chen, Princess Margaret Hospital, University Health Network; and Eric X. Chen, University of Toronto, Toronto, Ontario, Canada., Maillet D, Gan HK, Chen EX, You B
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2013 Nov 01; Vol. 31 (31), pp. 3957-63. Date of Electronic Publication: 2013 Sep 23.
Autor:
Jaume Capdevila, Arkadiy Klochikhin, Sophie Leboulleux, Pavel Isaev, Corin Badiu, Bruce Robinson, Brett G.M. Hughes, Bhumsuk Keam, Francis Parnis, Rossella Elisei, Pablo Gajate, Hui K. Gan, Ellen Kapiteijn, Laura Locati, Milan Mangeshkar, Leonardo Faoro, Jolanta Krajewska, Barbara Jarzab
Publikováno v:
Scientia
Thyroid Journal Program, 32(5), 515-524. MARY ANN LIEBERT, INC
Thyroid Journal Program, 32(5), 515-524. MARY ANN LIEBERT, INC
Cabozantinib; Medullary thyroid cancer; Tyrosine kinase inhibitor Cabozantinib; Càncer medul·lar de tiroides; Inhibidor de la tirosina cinasa Cabozantinib; Cáncer medular de tiroides; Inhibidor de la tirosina cinasa Background: Cabozantinib inhibi
Publikováno v:
Expert Review of Anticancer Therapy. 20:1057-1074
The importance of ErbB3 receptor tyrosine kinase in cancer progression, primary and acquired drug resistance, has become steadily evident since its discovery in 1989. ErbB3 overexpression in various solid organ malignancies is associated with shorter
Autor:
Peter J. Hudson, Pece Kocovski, Ian D. Davis, John Pedersen, Andrew M. Scott, Sze Ting Lee, Scott Williams, Fook-Thean Lee, Graeme O'Keefe, Tim Akhurst, Andrew Weickhardt, Hui K Gan, Michael Paul Wheatcroft, Maggie Oh, Marika Ciprotti, Fiona Scott, Sylvia J. Gong, Linda Mileshkin, Kunthi Pathmaraj, Nancy Guo, Declan G. Murphy, Rodney J. Hicks
Publikováno v:
Theranostics
Through protein engineering and a novel pegylation strategy, a diabody specific to tumor-associated glycoprotein 72 (TAG-72) (PEG-AVP0458) has been created to optimize pharmacokinetics and bioavailability to tumor. We report the preclinical and clini
Autor:
Hui K. Gan, Sagun Parakh, F. T. Lee, Niall C. Tebbutt, Malaka Ameratunga, Sze Ting Lee, Graeme J. O’Keefe, Sylvia J. Gong, Christine Vanrenen, Jaren Caine, Mara Giovannetti, Carmel Murone, Fiona E. Scott, Nancy Guo, Ingrid J. G. Burvenich, Cameron Paine, Mary J. Macri, Masakatsu Kotsuma, Giorgio Senaldi, Ralph Venhaus, Andrew M. Scott
Publikováno v:
Investigational new drugs. 40(4)
Ephrin type-A 2 (EphA2) is a transmembrane receptor expressed in epithelial cancers. We report on a phase I dose escalation and biodistribution study of DS-8895a, an anti-EphA2 antibody, in patients with advanced EphA2 positive cancers. DS-8895a was
Publikováno v:
Molecules, Vol 25, Iss 4764, p 4764 (2020)
Molecules
Molecules
Antibody–drug conjugates (ADCs) are novel drugs that exploit the specificity of a monoclonal antibody (mAb) to reach target antigens expressed on cancer cells for the delivery of a potent cytotoxic payload. ADCs provide a unique opportunity to deli
Autor:
Jason D, Lickliter, Hui K, Gan, Mark, Voskoboynik, Surein, Arulananda, Bo, Gao, Adnan, Nagrial, Peter, Grimison, Michelle, Harrison, Jianjun, Zou, Lianshan, Zhang, Stacey, Luo, Michael, Lahn, Howard, Kallender, Andrea, Mannucci, Catello, Somma, Katherine, Woods, Andreas, Behren, Pablo, Fernandez-Penas, Michael, Millward, Tarek, Meniawy
Publikováno v:
Drug Design, Development and Therapy
Purpose Camrelizumab inhibits PD-1 in non-clinical models and showed typical non-clinical pharmacokinetic (PK) and safety profiles for an IgG4 monoclonal antibody. We report results from the First-in-Human Phase 1 trial of camrelizumab in Australian
Autor:
Himanshu Brahmbhatt, Andrew M. Scott, Mark Rosenthal, James R. Whittle, Benjamin Solomon, Jason D. Lickliter, Hui K Gan, Jennifer A. MacDiarmid, John Simes
Publikováno v:
Journal of Clinical Neuroscience. 22:1889-1894
There are limited treatment options for patients with recurrent glioblastoma (GBM). The EnGeneIC delivery vehicle (EDV) is a novel nanocellular (minicell) compound which packages theoretically effective concentrations of chemotherapeutic drugs that a
Publikováno v:
The AAPS Journal. 20
The selection of therapeutic dose for the most effective treatment of tumours is an intricate interplay of factors. Molecular imaging with positron emission tomography (PET) or single-photon emission computed tomography (SPECT) can address questions
Autor:
Priya Kumthekar, Wijith Munasinghe, Helen Mandich, Martin J. van den Bent, Kyle D. Holen, JuDee Fischer, Hui K Gan, Ryan Merrell, Lisa Fichtel, Hao Xiong, Ho-Jin Lee, Lisa Roberts-Rapp, David A. Reardon, Erica Gomez, Erik P. Sulman, Andrew B. Lassman, Peter Ansell, Andrew M. Scott
Publikováno v:
Neuro-Oncology, 19(7), 965-975. Oxford University Press
Background. The purpose of this study was to determine the maximum tolerated dose (MTD), recommended phase II dose (RPTD), safety, and pharmacokinetics of ABT-414 plus radiation and temozolomide in newly diagnosed glioblastoma. ABT-414 is a first-in-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97d2d7c687a1e7f0d4238283cccda79f
https://pure.eur.nl/en/publications/8c228a80-05da-4b71-9733-64bd7d92be05
https://pure.eur.nl/en/publications/8c228a80-05da-4b71-9733-64bd7d92be05